Coherus Oncology, Inc. CHRS
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 50.94M | -- | -- | -- | 31.64M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 50.94M | -- | -- | -- | 31.64M |
| Cost of Revenue | 15.82M | -- | -- | -- | 11.53M |
| Gross Profit | 35.12M | -- | -- | -- | 20.11M |
| SG&A Expenses | 87.90M | -- | -- | -- | 109.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 204.93M | -- | -- | -- | 214.80M |
| Operating Income | -154.00M | -- | -- | -- | -183.16M |
| Income Before Tax | -161.15M | -- | -- | -- | -185.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -161.15 | -- | -- | -- | -185.95 |
| Earnings from Discontinued Operations | 29.01M | -- | -- | -- | 365.70M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -132.13M | -- | -- | -- | 179.75M |
| EBIT | -154.00M | -- | -- | -- | -183.16M |
| EBITDA | -150.39M | -- | -- | -- | -178.52M |
| EPS Basic | -1.03 | -- | -- | -- | 1.54 |
| Normalized Basic EPS | -0.76 | -- | -- | -- | -1.01 |
| EPS Diluted | -1.03 | -- | -- | -- | 1.54 |
| Normalized Diluted EPS | -0.76 | -- | -- | -- | -1.01 |
| Average Basic Shares Outstanding | 527.81M | -- | -- | -- | 462.56M |
| Average Diluted Shares Outstanding | 527.81M | -- | -- | -- | 462.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |